

For immediate release

August 15, 2019

## **NOVELOGICS WELCOMES DR. NEIL CLENDENINN AS CHIEF MEDICAL OFFICER**

Vancouver, BC – Novelogsics Biotechnology Inc. is welcoming Dr. Neil Clendeninn as the company's Chief Medical Officer. Dr. Clendeninn is an accomplished Senior Executive, Consultant, and Board Member with more than 35 years of success across the pharmaceutical, biotech, and medical industries.

Dr. Clendeninn has held leadership positions at companies including Heron Therapeutics, Kauai Hospice/Palliative Medicine Partners, OncoGenex Pharmaceuticals, CANAID Inc., Agouron Pharmaceuticals, and Burroughs Wellcome. He has extensive experience providing operations and regulatory guidance in drug development and being a valuable asset for companies working on preclinical development and early development learning technology pathways. His broad areas of expertise include oncology, dermatology, HIV, drug development, and clinical research. He has been responsible for developing the AIDS protease inhibitor Viracept (approved in record time of 36 months) at Agouron, where he led a 250-person staff before Pfizer acquired the company. As CMO at Heron, he was instrumental in gaining FDA approval for SUSTOL. As President and Drug Development Consultant with CANAID since 2001, he leads oncology advisory to the biotech industry. As Director and Co-Founder of Palliative Medicine Partners since 2012, he has developed a community-based program at Kauai Hospice to pilot palliative care pre-hospice. He previously worked for eight years as Director of the Clinical Oncology Department with Burroughs-Wellcome. Dr. Clendeninn served his Residency in Internal Medicine at the University of Washington, and trained with a Fellowship in Oncology & Clinical Pharmacology at the National Cancer Institute. He is a current Board Member with the Cancer Prevention & Research Initiative of Texas, and previously served on the Board of OncoGenex and Board of Scientific Advisors for the National Cancer Institute. As a recognized Thought Leader, he has authored more than 150 papers, abstracts and textbooks. Dr. Clendeninn attained an M.D. and Ph.D. in microbiology and pharmacology from New York University.

"We are very pleased to have Dr. Clendeninn join our team as Chief Medical Officer. His decades of experience and strong track record in drug development will be pivotal as we progress toward IND filing with the FDA and a Phase 1 clinical trial. I am confident that Dr. Clendeninn's guidance will allow us to work towards our goal of developing therapeutics to improve the lives of cancer patients," stated Elaine Allison, Chief Executive Officer of Novelogsics.

In addition to welcoming Dr. Clendeninn this year, Novelogsics has also hired Dr. Mark Bazett as Preclinical Immunotherapy Lead and Matthew Sebastiani as Vice President of Finance and Operations. Earlier this month, Elaine Allison was appointed as CEO.

## **About Novelogics Biotechnology, Inc.**

Novelogics Biotechnology Inc. is a Vancouver, Canada-based, privately-held biotechnology company dedicated to developing innovative cancer immunotherapy treatments that harness the power of the immune system. It has internally developed a proprietary antibody immunotherapy for cancer using a novel “Interceptor” approach. Its product candidate is designed to overcome key strategies that are used by cancer cells to evade the immune system and that also induce unwanted immune suppression. The drug target of Novelogics’ product candidate is found in blood cancers and solid tumors, as well as other significant diseases, which offers the opportunity to develop a treatment with broad therapeutic potential. Novelogics’ immunotherapy strategy focuses on the development of antibody drugs that could dramatically challenge the status quo on current approaches in the exciting field of immuno-oncology.

### **Contact Information**

Novelogics Biotechnology Inc.

Elaine Allison, CEO

Email: [info@novelogics.com](mailto:info@novelogics.com)

###

*This communication may contain statements related to future, not past, events. These may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. These statements reflect our opinions only as of the date of this communication. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events.*